Jessica B Rubin1, Bilal Hameed1, Michelle Gottfried2, William M Lee3, Monika Sarkar4. 1. Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California. 2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina. 3. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California. Electronic address: monika.sarkar@ucsf.edu.
Abstract
BACKGROUND & AIMS: Acetaminophen overdose is the leading cause of acute liver injury (ALI) and acute liver failure (ALF) in the developed world. Sex differences in acetaminophen-induced hepatotoxicity have not been described. METHODS: We collected data from the Acute Liver Failure Study Group cohort, a national registry of 32 academic medical centers in North America of adults with ALI or ALF, including 1162 patients with acetaminophen-induced ALI (n = 250) or acetaminophen-induced ALF (n = 912) from January 2000 through September 2016. We analyzed data on patient presentation, disease course, demographics, medical and psychiatric history, medication use, substance use, and details of acetaminophen ingestion. Sex differences in continuous and categorical variables were evaluated by Wilcoxon rank-sum and χ2 analysis or the Fisher exact test. Our primary aim was to evaluate sex differences in the presentation and clinical course of acetaminophen-induced acute liver injury or liver failure, and our secondary goal was to compare overall and transplant-free survival between sexes. RESULTS: Most patients with acetaminophen-induced ALI (68%) or ALF (76%) were women. Higher proportions of women than men had psychiatric disease (60% of women vs 48% of men, P < .01) and had co-ingestion with sedating agents (70% of women vs 52% of men, P < .01)-more than half of which were opioids. Higher proportions of women had severe hepatic encephalopathy (HE) (68% of women vs 58% of men), and required intubation (67% of women vs 59% of men, P values <.03). Higher proportions of women used vasopressors (26% of women vs 19% of men, P = .04) or mannitol (13% of women vs 6% of men, P < .01); proportions of male vs female patients with transplant-free survival were similar (68%). On adjusted analysis, women had higher risk of severe HE (adjusted odds ratio [AOR], 1.66; 95% CI, 1.17-2.35). We found a significant interaction between sex and co-ingestion of sedating agents (P < .01); co-ingestion increased odds of severe HE in women 2-fold (AOR, 1.86; 95% CI, 1.28-2.69; P < .01) but not in men (AOR; 0.62; 95% CI, 0.34-1.13; P = .12). CONCLUSIONS: In an analysis of the Acute Liver Failure Study Group cohort, we found acetaminophen-induced ALI and ALF to be more common among women. Women have greater critical care needs than men, and increased risk for severe HE, which could be due in part to increased use of sedatives. Future studies should investigate sex differences in acetaminophen metabolism and hepatotoxicity, particularly among users of opioids.
BACKGROUND & AIMS:Acetaminophenoverdose is the leading cause of acute liver injury (ALI) and acute liver failure (ALF) in the developed world. Sex differences in acetaminophen-induced hepatotoxicity have not been described. METHODS: We collected data from the Acute Liver Failure Study Group cohort, a national registry of 32 academic medical centers in North America of adults with ALI or ALF, including 1162 patients with acetaminophen-induced ALI (n = 250) or acetaminophen-induced ALF (n = 912) from January 2000 through September 2016. We analyzed data on patient presentation, disease course, demographics, medical and psychiatric history, medication use, substance use, and details of acetaminophen ingestion. Sex differences in continuous and categorical variables were evaluated by Wilcoxon rank-sum and χ2 analysis or the Fisher exact test. Our primary aim was to evaluate sex differences in the presentation and clinical course of acetaminophen-induced acute liver injury or liver failure, and our secondary goal was to compare overall and transplant-free survival between sexes. RESULTS: Most patients with acetaminophen-induced ALI (68%) or ALF (76%) were women. Higher proportions of women than men had psychiatric disease (60% of women vs 48% of men, P < .01) and had co-ingestion with sedating agents (70% of women vs 52% of men, P < .01)-more than half of which were opioids. Higher proportions of women had severe hepatic encephalopathy (HE) (68% of women vs 58% of men), and required intubation (67% of women vs 59% of men, P values <.03). Higher proportions of women used vasopressors (26% of women vs 19% of men, P = .04) or mannitol (13% of women vs 6% of men, P < .01); proportions of male vs female patients with transplant-free survival were similar (68%). On adjusted analysis, women had higher risk of severe HE (adjusted odds ratio [AOR], 1.66; 95% CI, 1.17-2.35). We found a significant interaction between sex and co-ingestion of sedating agents (P < .01); co-ingestion increased odds of severe HE in women 2-fold (AOR, 1.86; 95% CI, 1.28-2.69; P < .01) but not in men (AOR; 0.62; 95% CI, 0.34-1.13; P = .12). CONCLUSIONS: In an analysis of the Acute Liver Failure Study Group cohort, we found acetaminophen-induced ALI and ALF to be more common among women. Women have greater critical care needs than men, and increased risk for severe HE, which could be due in part to increased use of sedatives. Future studies should investigate sex differences in acetaminophen metabolism and hepatotoxicity, particularly among users of opioids.
Authors: Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei Journal: Hepatology Date: 2002-03 Impact factor: 17.425
Authors: G Wei; A Bergquist; U Broomé; S Lindgren; S Wallerstedt; S Almer; P Sangfelt; A Danielsson; H Sandberg-Gertzén; L Lööf; H Prytz; E Björnsson Journal: J Intern Med Date: 2007-09 Impact factor: 8.989
Authors: Jessica K Paulus; Lana Y H Lai; Christine Lundquist; Ali Daneshmand; Hannah Buettner; Jennifer S Lutz; Gowri Raman; Benjamin S Wessler; David M Kent Journal: J Am Heart Assoc Date: 2016-05-05 Impact factor: 5.501
Authors: Sanda Win; Robert Wm Min; Christopher Q Chen; Jun Zhang; Yibu Chen; Meng Li; Ayako Suzuki; Manal F Abdelmalek; Ying Wang; Mariam Aghajan; Filbert Wm Aung; Anna Mae Diehl; Roger J Davis; Tin A Than; Neil Kaplowitz Journal: J Clin Invest Date: 2019-12-02 Impact factor: 14.808
Authors: Nga T Nguyen; Kuo Du; Jephte Y Akakpo; David S Umbaugh; Hartmut Jaeschke; Anup Ramachandran Journal: Toxicol Lett Date: 2020-12-05 Impact factor: 4.372
Authors: Melissa M Clemens; Stefanie Kennon-McGill; Joel H Vazquez; Owen W Stephens; Erich A Peterson; Donald J Johann; Felicia D Allard; Eric U Yee; Sandra S McCullough; Laura P James; Brian N Finck; Mitchell R McGill Journal: Acta Pharm Sin B Date: 2021-08-26 Impact factor: 11.413
Authors: Alexandre Nuzzo; Shireen Salem; Isabelle Malissin; Abdourahmane Diallo; Nicolas Deye; Antoine Goury; Hervé Gourlain; Nicolas Péron; Eric Vicaut; Sebastian Voicu; Bruno Mégarbane Journal: United European Gastroenterol J Date: 2021-06 Impact factor: 4.623